Soc. Generale Knock-Out PGR/ DE000SY41Z69 /
2024-08-30 6:44:54 PM | Chg.+0.02 | Bid7:07:54 PM | Ask7:07:54 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.09EUR | +1.87% | 1.13 Bid Size: 30,000 |
1.15 Ask Size: 30,000 |
Progressive Corporat... | 238.6632 USD | 2078-12-31 | Call |
GlobeNewswire
08-19
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
GlobeNewswire
08-19
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire
08-15
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
08-14
Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene ...
GlobeNewswire
08-14
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
GlobeNewswire
08-13
Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire
08-12
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Newsfile Corp
08-12
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
08-08
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15,...
GlobeNewswire
08-07
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Sus...
GlobeNewswire
08-07
AGS Unveils its Latest Table Innovation Bonus Spin Xtreme for Poker Rooms and an Exciting New Lineup...
GlobeNewswire
08-07
Team, Inc. Announces Timing of Second Quarter Earnings Release and Conference Call
GlobeNewswire
08-06
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy)...
GlobeNewswire
08-06
Levicept Announces Positive Results of Phase II Trial of novel Neurotrophin-3 Inhibitor, LEVI-04, fo...
GlobeNewswire
08-05
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted...